Product Description
OP-1250 is a small molecule Complete Estrogen Receptor ANtagonist (CERAN). OP-1250 potently competes with the endogenous activating estrogenic ligand 17-beta estradiol for binding in the ligand binding pocket. OP-1250 blocks estrogen-driven transcriptional activity, inhibits estrogen-driven breast cancer cell growth, and induces degradation of the estrogen receptor.
Mechanisms of Action: ER Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Breast Cancer|Oncology Solid Tumor Unspecified *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Olema Pharmaceuticals
Company Location: SAN FRANCISCO CA 94107
Company CEO: Sean Bohen
Additonal Commercial Interests: Aurigene Discovery Technologies
Clinical Description

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czech Republic, France, Germany, Hong Kong, Hungary, Italy, Korea, Malaysia, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Spain, Taiwan, Thailand, United Kingdom, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
OP-1250-301 | P3 |
Unknown Status |
Breast Cancer |
2027-11-30 |
|
OPERA-01 | P3 |
Active, not recruiting |
Breast Cancer |
2026-06-30 |
|
OP-1250-002 | P1 |
Active, not recruiting |
Breast Cancer |
2025-01-01 |
44% |
OP-1250-001 | P2 |
Active, not recruiting |
Breast Cancer |
2024-06-01 |
57% |